CIK 0001582313
- Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- Operating
- EIN
- 980661854
- Phone
- +1 604-484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-18 | TARNOW MICHAEL M Director | Exercise or conversion · Stock Option (Right to Buy) | −1,028 | 0 | ||
| 2021-05-18 | TARNOW MICHAEL M Director | Exercise or conversion · Stock Option (Right to Buy) | −5,144 | 0 | ||
| 2021-05-18 | Hayden Michael R Director | Exercise or conversion | +3,500 | $3.85 | $13K | 116,206 |
| 2021-05-18 | Hayden Michael R Director | Exercise or conversion · Stock Option (Right to Buy) | −3,500 | 0 | ||
| 2021-03-17 | PATOU GARY Director | Other acquisition | +100 | $19.49 | $2K | 100 |
| 2021-03-12 | Von Seggern Christopher Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2021-03-12 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2021-03-12 | PIMSTONE SIMON N. CEO | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2021-03-12 | MORTIMER IAN PRESIDENT & CFO | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2021-03-12 | EMPFIELD JAMES R. EVP, Drug Discovery | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2021-02-18 | Hayden Michael R Director | Exercise or conversion | +10,288 | $3.67 | $38K | 61,212 |
| 2021-02-18 | Hayden Michael R Director | Exercise or conversion | +30,864 | $2.68 | $83K | 92,076 |
| 2021-02-18 | Hayden Michael R Director | Exercise or conversion · Stock Option (Right to Buy) | −10,288 | 0 | ||
| 2021-02-18 | Hayden Michael R Director | Exercise or conversion · Stock Option (Right to Buy) | −30,864 | 0 | ||
| 2021-02-16 | Hayden Michael R Director | Exercise or conversion | +5,144 | $2.68 | $14K | 112,706 |
| 2021-02-16 | Hayden Michael R Director | Exercise or conversion · Stock Option (Right to Buy) | −5,144 | 0 | ||
| 2020-12-15 | AZAB MOHAMMAD Director | Exercise or conversion | +3,086 | $3.76 | $12K | 63,733 |
| 2020-12-15 | AZAB MOHAMMAD Director | Exercise or conversion · Stock Option (Right to Buy) | −3,086 | 0 | ||
| 2020-11-05 | Machado Patrick Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2020-10-28 | TARNOW MICHAEL M Director | Exercise or conversion | +5,144 | $3.76 | $19K | 74,857 |
Page 21 of 27 · 536 trades